Steven Pieper - 10 Nov 2021 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Financial Officer
Signature: /s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 10 Nov 2021
Net transactions value: +$49,918
Form type: 4
Filing time: 12 Nov 2021, 16:06:17 UTC
Previous filing: 05 Oct 2021
Next filing: 05 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Purchase	$49,918	+25,000	+16%	$2.00	183,108	10 Nov 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Content

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

Chief Financial Officer